KLK3 and prostate carcinoma: In cancer diagnostics, by utilizing Simoa, prostate-specific antigen (PSA) has a thousand-fold lower limit of quantification (< 0.01 pg/mL) than conventional ultrasensitive PSA assays, which allows for monitoring recurrence of prostate cancer after radical prostatectomy [31–33].